https://pharminent.com/strategic-news-watch/strategic-news-watch-august-20-2026/ 2026-08-20T18:47:56Z Pharminent en Strategic News Watch • August 20, 2026 2026-08-20T18:47:54Z Blog https://pharminent.com/moderna-and-mercks-personalized-melanoma-vaccine-scores-historic-phase-3-win/ 2026-08-20T18:59:00Z Pharminent en Moderna and Merck's Personalized Melanoma Vaccine Scores Historic Phase 3 Win 2026-08-19T19:13:23Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-august-19-2026/ 2026-08-19T18:54:51Z Pharminent en Strategic News Watch • August 19, 2026 2026-08-19T18:54:48Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-august-17-2026/ 2026-08-18T20:34:07Z Pharminent en Rare Disease & Gene Therapy Digest • August 17, 2026 2026-08-18T20:34:05Z Blog https://pharminent.com/amylyxs-avexitide-succeeds-in-phase-3-pivotal-study-for-post-bariatric-hypoglycemia/ 2026-08-19T18:45:35Z Pharminent en Amylyx's Avexitide Succeeds in Phase 3 Pivotal Study for Post-Bariatric Hypoglycemia 2026-08-18T19:37:49Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-august-18-2026/ 2026-08-18T19:06:09Z Pharminent en Strategic News Watch • August 18, 2026 2026-08-18T19:06:05Z Blog